February 15, 2022 7:43am

Following huge pull-backs

Pre-open indications:  10 BUYs, 4 SELLs and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Only the facts … I ask questions and note the probabilities

Dow futures are UP +1.24% (+429 points), S&P futures are UP +1.60% (+71 points) and NASDAQ futures are UP +2.16% (+308 points)

 

U.S. stock futures are flying on Tuesday morning having cooled geopolitical tensions that knocked equities down in the last three (3) sessions,

European markets jumped with the pan-European Stoxx 600 index climbing +1%.

Asia-Pacific markets were mixed with Japan and Hong Kong closed down as Mainland Chinese closed higher.

 

Henry’omics:

Russian Defense Ministry spokesman Igor Konashenkov said “troops who had recently been posted to Russia’s southern and western military districts — which share a border with Ukraine — had completed their drills” and “have already begun loading onto rail and road transport and will begin moving to their military garrisons today.” <CNBC)

As sarcasm reigns … as multiple Fed rate hikes should keep investors cautious.

 

If you didn’t remember what happen at Monday’s close, you won’t be prepared for today’s session,

RegMed Investors’ (RMi) closing bell: “interpreting the cell and gene therapy sector’s decline. Weakness from geopolitical headlines, Fed’s credibility and yet another earnings’ slip” …  https://www.regmedinvestors.com/articles/12300

 

Ebb and flow:

  • February stats: 6 negative and 4 positive closes
  • January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

Probabilities/ Potentials pre-open share pricing indication moves:

 

BUY on response: the trend after the bend … tips and slips

Adverum Biotechnologies (ADVM),

CRISPR Therapeutics (CRSP),

Editas Medicine (EDIT),

Ionis Pharmaceuticals (IONS),

MiMedx (MDXG),

Intellia Therapeutics (NTLA),

Pluristem (PSTI),

UniQure NV (QURE),

ReNeuron (RENE.L),

Solid Biosciences (SLDB),

 

SELL:

Applied Genetic Technologies (AGTC),

Brainstorm Cell Therapeutics (BCLI),

Sage Therapeutics (SAGE),

Voyager Therapeutics (VYGR),

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed flat on Monday with 1,899 shares traded after

Friday’s -$0.02 with 1,739 shares traded after Thursday’s +$0.60 to $4.58 with 2,841 shares traded, Wednesday’s -$0.61 with 4,030 shares traded, Tuesday’s +$0.05 to $4.59 with 1,293 shares traded and Monday’s +$0.55 with 2,311 shares traded,

The previous Friday’s +$0.22 with 305 shares traded, Thursday’s flat (-$0.00) with 3 shares traded, Wednesday’s -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares traded, Monday’s flat with 11 shares traded,

And the preceding Friday’s +$0.05 to $3.90 with 3,362 shares traded, Thursday’s +$0.24 to $3.85 with 10,073 shares traded.

  • WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position overseen?
  • Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering- they’re NOT going ANYWHERE without a cash inflow.

 

 

The BOTTOM LINE: a new tailwind for global markets as worried slip but, are not diminishing the geopolitical conflict with a potential for exacerbated inflation, Fed tightening and earnings’ disruptions.

I continue my skittishness regarding earnings’ reporting and the volatility in trading that usually precedes and follows releases.

Reiterating, “the cell and gene therapy sector’s relative valuation metrics suggest earnings reports are about to hit and I believe, hard.”

Investors have to recognize what kind of market we are in – VOLATILE with LOW VOLUME. Which gives us reasons to be cautious.

Earnings’ reporting:

  • AxoGen AXGN) – 2/22, Tuesday, 2/22
  • Sage Therapeutics (SAGE), Thursday, 2/24
  • Ionis Pharmaceuticals (IONS), Thursday, 2/24

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q1/22 waiting for Q4 and FY21 numbers”.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.